Irfan Admani, Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 103 River Road, Edgewater, NJ 07020 Phone: 201-941-8100 Fax: 201-941-2899 |
Dr. Fernando Segovia, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 103 River Rd, Edgewater, NJ 07020 Phone: 201-941-8100 Fax: 201-941-2899 |
Dr. Yaron Bareket, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 103 River Rd, Edgewater, NJ 07020 Phone: 201-941-8100 Fax: 201-941-2899 |
Dr. Rick Pumill, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 103 River Rd, Edgewater, NJ 07020 Phone: 201-941-8100 Fax: 201-941-2899 |
Radu Codel, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 968 River Rd, Edgewater, NJ 07020 Phone: 201-969-0994 Fax: 201-969-2453 |
News Archive
Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.
A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will treat patients with relapsed or refractory acute myeloid leukemia using a novel universal natural killer cell approach.
Banyan Biomarkers, Inc., a pioneer in developing biomarkers for traumatic brain injury (TBI), today announced the publication of the results for the ALERT-TBI study, an international, multicenter clinical trial utilizing the Banyan Brain Trauma Indicator.
Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine's current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.
News outlets also report on how other changes are affecting small business owners, hospitals and students.
› Verified 5 days ago